| Acute (n = 137) | Chronic (n = 316) | Healthy (n = 146) | Inapparent (n = 35) | Recovery (n = 99) | P-value | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Subgrouping criteria | ||||||||||||
 Epidemiologic exposure history | + | + |  ±  | + | + | – | ||||||
 Symptoms and signs | + | + | − | + | + | – | ||||||
 Rose Bengal Plate agglutination Test | + | + | + | +  | + | – | ||||||
 Standard agglutination test | + | + | + | +  | + | – | ||||||
 Holding time (Months) |  ≤ 6 |  > 6 | − | Unknown | Unknown | – | ||||||
 Medication history | +  | +  | − | − | +  | – | ||||||
Demographic features | ||||||||||||
 Gender (Male/Female) | 95/42 | 240/76 | 105/41 | 26/9 | 77/22 | 0.519 | ||||||
 Age (Years) | 50.65 ± 11.36 | 53.28 ± 9.33 | 49.38 ± 12.90 | 46.71 ± 10.37 | 51.01 ± 10.01 |  < 0.001 | ||||||
Hematology | ||||||||||||
 Red blood cells (× 1012/L) | 4.98 ± 0.59 | 4.96 ± 0.57 | 4.92 ± 0.75 | 5.04 ± 0.51 | 5.04 ± 0.49 | 0.567 | ||||||
 Hemoglobin (g/L) | 146.41 ± 20.60 | 149.54 ± 16.23 | 146.58 ± 22.32 | 150.69 ± 16.39 | 150.98 ± 15.25 | 0.157 | ||||||
 White blood cells (× 109/L) | 5.48 ± 1.46 | 5.64 ± 1.52 | 5.82 ± 1.59 | 5.94 ± 1.46 | 5.93 ± 1.69 | 0.127 | ||||||
 Lymphocyte (× 109/L) | 1.94 ± 0.61 | 1.87 ± 0.58 | 1.88 ± 0.60 | 1.85 ± 0.43 | 1.97 ± 0.66 | 0.493 | ||||||
 Neutrophil (× 109/L) | 2.95 ± 1.38 | 3.27 ± 1.33 | 3.45 ± 1.42 | 3.67 ± 1.30 | 3.57 ± 1.30 | 0.001 | ||||||
 Platelets (× 109/L) | 171.92 ± 67.54 | 169.96 ± 65.17 | 172.79 ± 61.00 | 170.97 ± 55.86 | 157.38 ± 49.38 | 0.361 | ||||||
 Neutrophil/lymphocyte ratio | 1.62 ± 0.91 | 1.85 ± 0.89 | 1.98 ± 1.06 | 2.08 ± 0.97 | 1.98 ± 1.11 | 0.009 | ||||||
 Platelets/lymphocyte ratio | 81.64 ± 25.68 | 86.84 ± 24.60 | 84.42 ± 24.60 | 84.85 ± 18.09 | 86.37 ± 36.90 | 0.449 | ||||||
Serum biochemistry | ||||||||||||
 Alanine transaminase (U/L) | 31.28 ± 27.83 | 28.02 ± 19.05 | 26.93 ± 16.24 | 26.74 ± 21.72 | 32.90 ± 20.88 | 0.107 |